Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で365.51%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 1.34Mに達しています。
適正水準
同社の最新のPEは-1.27で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は4.98M株で、前四半期比で9.41%増加しています。
ジェームズ・シモンズが保有
スター投資家ジェームズ・シモンズは本銘柄を27.42K株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.76です。